Pharmacotherapy’s impact factor (IF) has reached an all-time high.

Impact factors are published each year by Clarivate Analytics, a company providing multiple products pertaining to scientific research insights. The IF reflects a journal’s performance and status through a record of how often its articles are cited in other biomedical journals. The release of IF data is eagerly awaited each year by publishers and editorial teams. The data released June 28 ranked journals with respect to citations during 2021 of articles published during 2019–2020.

The IF for Pharmacotherapy has increased to 6.215. This 33% increase can be put into a different perspective by understanding how Pharmacotherapy is ranked within its designated journal category, Pharmacy and Pharmacology. The increase from last year’s value of 4.705 launches Pharmacotherapy’s IF well into the top quartile of Pharmacy and Pharmacology journals. Last year, Pharmacotherapy ranked 74th out of 275 journals. This year, Pharmacotherapy improved to a ranking of 44th out of 279 journals.

The IF should not be the sole measure of journal quality, but it remains a vital measure in biomedical publishing of the impact of a journal on its field. A journal’s citation metrics alongside data on downloads, international readership, and comparisons with other journals are all measures of its success.

The publication of Pharmacotherapy is made possible through the combined effort of many individuals, including publication staff, editors, editorial board members, and reviewers. Most important are the authors who choose to submit their best work to the journal.

The top 10 articles published in 2019–2020 with the most citations in 2021 are as follows.

1. Tsuji BT, Pogue JM, Zavascki AP, et al. International Consensus Guidelines for the Optimal Use of the Polymyxins.
2. Jorgensen SCJ, Kebriaei R, Dresser LD. Remdesivir: Review of Pharmacology, Pre-clinical Data, and Emerging Clinical Experience for COVID-19.
3. Barlow A, Landolf KM, Barlow B, et al. Review of Emerging Pharmacotherapy for the Treatment of Coronavirus Disease 2019.
4. Jorgensen SCJ, Tse CLY, Burry L, Dresser LD. Baricitinib: A Review of Pharmacology, Safety, and Emerging Clinical Experience in COVID-19.
5. Teshome BF, Vouri SM, Hampton N, Kollef MH, Micek ST. Duration of Exposure to Antipseudomonal ß-Lactam Antibiotics in the Critically Ill and Development of New Resistance.
6. Cook AM, Hatton-Kolpek J. Augmented Renal Clearance.
7. Johnson KM, Belfer JJ, Peterson GR, Boelkins MR, Dumkow LE. Managing COVID-19 in Renal Transplant Recipients: A Review of Recent Literature and Case Supporting Corticosteroid-Sparing Immunosuppression.
8. Perreault S, de Denus S, White-Guay B, et al. Oral Anticoagulant Prescription Trends, Profile Use, and Determinants of Adherence in Patients with Atrial Fibrillation.
9. Meng L, Wong T, Huang S, et al. Conversion from Vancomycin Trough Concentration–Guided Dosing to Area Under the Curve–Guided Dosing Using Two Sample Measurements in Adults: Implementation at an Academic Medical Center.
10. Flowers SA, Baxter NT, Ward KM, et al. Effects of Atypical Antipsychotic Treatment and Resistant Starch Supplementation on Gut Microbiome Composition in a Cohort of Patients with Bipolar Disorder or Schizophrenia.